CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
ConditionGeneralized Pustular Psoriasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCorEvitas
About this trial
Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner.
Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.
Is willing to provide consent for participation in the registry.
Is willing to provide Personal Information
Disqualifiers
Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP.
Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry
Trial population
Subjects are enrolled in the GPP Registry during regularly scheduled office visits. Selected dermatologists are invited to participate as investigators in the Registry.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: Generalized Pustular Psoriasis (GPP)
Trial outcomes
Primary outcomes
1
Primary Outcome Measure:GPP epidemiology and Presentation
The major clinical outcomes include an assessment of the epidemiology of GPP; to better understand the presentation and natural history.
Time frame
Through study completion, an average of 10 years2
GPP management, and outcomes
The major clinical outcome include an assessment of the epidemiology of GPP; to better understand the management and outcomes.
Time frame
Through study completion, an average of 10 years Source ClinicalTrials.gov